Disease-causing mutations in shared genes produce tissue-specific phenotypes because the mutant protein exhibits differential incorporation into multi-protein complexes based on tissue-specific expression of complex subunits and post-translational modifications. In affected neuronal tissues, the mutation preferentially disrupts complexes essential for synaptic function, axonal transport, or mitochondrial dynamics, while unaffected tissues compensate through alternative complex compositions or protective PTM states. This predicts that identical pathogenic variants should show measurable differences in interactome perturbations when comparing affected versus unaffected patient-derived tissues, and that engineering protein-protein interactions to stabilize disease-relevant complexes should rescue the neuronal phenotype without affecting peripheral tissues.
Curated pathway from expert analysis
flowchart TD
A["Protein Complex<br/>Assembly"]
B["Complex Stability<br/>Quality Control"]
C["Interactome<br/>Destabilization"]
D["Phenotypic Divergence<br/>in Neurological Disease"]
E["Protein Homeostasis<br/>Network Stress"]
F["Complex Assembly<br/>as Therapeutic Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patient-derived neurons (affected tissue) are compared to patient-matched fibroblasts or lymphoblasts (unaffected tissue) from carriers of identical pathogenic variants in shared Mendelian neurolog | Quantitative co-immunoprecipitation or BioID-MS will detect significantly greater disruption of disease-relevant protein complexes in neurons (fold-change >0.5 | — no observation — | pending | 0.65 |
| IF protein-protein interaction stabilizing mutations or small molecule PPI agonists are applied to patient-derived neurons carrying disease-causing variants to preferentially reinforce complexes essen | Neuronal phenotypic rescue: >30% improvement in mitochondrial aspect ratio, synaptic density, or axonal transport velocity compared to untreated patient neurons | — no observation — | pending | 0.55 |